TSEC:4119

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

SCI Pharmtech, Inc. develops, produces, and sells active pharmaceutical ingredients, intermediates, and custom products worldwide. More Details


Snowflake Analysis

Flawless balance sheet with solid track record and pays a dividend.

Share Price & News

How has SCI Pharmtech's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 4119 is more volatile than 75% of TW stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: 4119's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of TW stocks.


Market Performance


7 Day Return

-7.5%

4119

-2.4%

TW Pharmaceuticals

2.5%

TW Market


1 Year Return

-9.3%

4119

28.2%

TW Pharmaceuticals

31.6%

TW Market

Return vs Industry: 4119 underperformed the TW Pharmaceuticals industry which returned 28.2% over the past year.

Return vs Market: 4119 underperformed the TW Market which returned 31.6% over the past year.


Shareholder returns

4119IndustryMarket
7 Day-7.5%-2.4%2.5%
30 Day13.6%-10.2%11.8%
90 Day-22.8%-21.6%22.9%
1 Year-5.1%-9.3%30.4%28.2%36.3%31.6%
3 Year74.6%55.5%34.3%27.1%59.7%41.8%
5 Year57.8%26.4%6.4%-1.6%136.2%94.8%

Long-Term Price Volatility Vs. Market

How volatile is SCI Pharmtech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is SCI Pharmtech undervalued compared to its fair value and its price relative to the market?

10.15x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 4119 (NT$93) is trading above our estimate of fair value (NT$43.45)

Significantly Below Fair Value: 4119 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 4119 is good value based on its PE Ratio (10.1x) compared to the TW Pharmaceuticals industry average (17.3x).

PE vs Market: 4119 is good value based on its PE Ratio (10.1x) compared to the TW market (18.4x).


Price to Earnings Growth Ratio

PEG Ratio: 4119 is good value based on its PEG Ratio (0.7x)


Price to Book Ratio

PB vs Industry: 4119's PB Ratio (2x) is in line with the TW Pharmaceuticals industry average.


Next Steps

Future Growth

How is SCI Pharmtech forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

14.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4119's forecast earnings growth (14.8% per year) is above the savings rate (0.8%).

Earnings vs Market: 4119's earnings (14.8% per year) are forecast to grow slower than the TW market (18.6% per year).

High Growth Earnings: 4119's earnings are forecast to grow, but not significantly.

Revenue vs Market: 4119's revenue is expected to decline over the next 3 years (-31.4% per year).

High Growth Revenue: 4119's revenue is forecast to decline over the next 3 years (-31.4% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 4119's Return on Equity is forecast to be low in 3 years time (10.4%).


Next Steps

Past Performance

How has SCI Pharmtech performed over the past 5 years?

15.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4119 has high quality earnings.

Growing Profit Margin: 4119's current net profit margins (26.9%) are higher than last year (25.7%).


Past Earnings Growth Analysis

Earnings Trend: 4119's earnings have grown by 15.4% per year over the past 5 years.

Accelerating Growth: 4119's earnings growth over the past year (23.1%) exceeds its 5-year average (15.4% per year).

Earnings vs Industry: 4119 earnings growth over the past year (23.1%) underperformed the Pharmaceuticals industry 23.3%.


Return on Equity

High ROE: 4119's Return on Equity (20.1%) is considered high.


Next Steps

Financial Health

How is SCI Pharmtech's financial position?


Financial Position Analysis

Short Term Liabilities: 4119's short term assets (NT$1.4B) exceed its short term liabilities (NT$595.2M).

Long Term Liabilities: 4119's short term assets (NT$1.4B) exceed its long term liabilities (NT$22.3M).


Debt to Equity History and Analysis

Debt Level: 4119 is debt free.

Reducing Debt: 4119 had no debt 5 years ago.

Debt Coverage: 4119 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 4119 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is SCI Pharmtech current dividend yield, its reliability and sustainability?

6.24%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 4119's dividend (6.24%) is higher than the bottom 25% of dividend payers in the TW market (2.1%).

High Dividend: 4119's dividend (6.24%) is in the top 25% of dividend payers in the TW market (5.16%)


Stability and Growth of Payments

Stable Dividend: 4119 has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: 4119's dividend payments have increased, but the company has only paid a dividend for 6 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (63.3%), 4119's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: 4119's dividends in 3 years are forecast to be covered by earnings (50.7% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Yon-Lian Wu

no data

Tenure

Dr. Yon-Lian Wu serves as the Chief Executive Officer of SCI Pharmtech, Inc.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.5%.


Top Shareholders

Company Information

SCI Pharmtech, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: SCI Pharmtech, Inc.
  • Ticker: 4119
  • Exchange: TSEC
  • Founded: 1987
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NT$7.392b
  • Shares outstanding: 79.49m
  • Website: https://www.sci-pharmtech.com.tw

Number of Employees


Location

  • SCI Pharmtech, Inc.
  • No. 61, Haihu North Road
  • Lane 309
  • Taoyuan City
  • 33856
  • Taiwan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4119TSEC (Taiwan Stock Exchange)YesCommon StockTWTWDJan 2004

Biography

SCI Pharmtech, Inc. develops, produces, and sells active pharmaceutical ingredients, intermediates, and custom products worldwide. Its active pharmaceutical ingredients include allopurinol, amobarbital, pr...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/23 08:49
End of Day Share Price2021/01/22 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.